the aid library

LIST OPTIONS

Filter

13170

Independent Monitoring Board of the Global Polio Eradication Initiative (Fifteenth Report: December 2017)

Global Polio Eradication Initiative (2017) C1

The report reviews progress with the task of planning and implementing measures necessary to secure a completely polio-free world. It also examines actions aimed at ensuring successful transfer of polio assets, innovations developed and lessons learned to countries’ public health programmes and ot... more

Download (1020)

View PDF (929)

Namibia: Nutrition guidelines for prevention and management of non-communicable diet related disease

Ministry of Health and Social Services (MOHSS) (2013) C1

Download (182)

View PDF (202)

Nurses as substitutes for doctors in primary care - Review

Laurant M, van der Biezen M, Wijers N et al. Cochrane Library (2018) CC

Current and expected problems such as ageing, increased prevalence of chronic conditions and multi-morbidity, increased emphasison healthy lifestyle and prevention, and substitution for care from hospitals by care provided in the community encourage countries worldwide to develop new models of prima... more

Download (53)

View PDF (57)

Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment

Fuss, A.; H. D. Mazigo and A. Mueller (2020) CC

Infectious Diseases of Poverty (2020) 9:74 To detect acute schistosomiasis, low-intensity infections, or to verify the success of treatment with praziquantel, highly sensitive test methods are required. The aim of this study was therefore to demonstrate the performance of Schistosoma mansoni spec... more

External Link

Questions and Answers for Obstetrical Healthcare Providers: Pregnant Women and Zika Virus Infection

Centers for Disease Control and Prevention CDC (2022) C_CDC

English version

Download (198)

View PDF (201)

COVID-19: Guidelines for communicating about coronavirus disease 2019 - A guide for leaders

Pan American Health Organisation PAHO (2020) C_WHO

Risk communication encompasses all the basics of health communication but differs in the need for speed and reliance on trust. At times of crisis, leaders are called on to provide a quick, sensitive and trustworthy response.

Download (216)

View PDF (304)

Trastorno por déficit de atención con hiperactividad

T. S. Moriyama; A. J. M. Cho; R. E. Verin; et al. IACAPAP (2017) C2

Trastornos externalizantes Capítulo D.1 Edición: Matías Irarrázaval & Andrés Martín Traducción: Fernanda Prieto Tagle, Marta García Acuña

Download (264)

View PDF (275)

Multi-Professional Patient Safety Curriculum Guide

World Health Organization WHO (2011) C_WHO

The Multi-professional Patient Safety Curriculum Guide (2011) was developed to assist in the teaching of patient safety in universities and schools in the fields of dentistry, medicine, midwifery, nursing and pharmacy. It also supports the on-going training of all health care professionals. The C... more

Download (394)

View PDF (156)

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov... more

Download (102)

View PDF (107)

Breast and cervical cancer screening services in Malawi: a systematic review

Pittalis, C.; Panteli, E.; Schouten, E. et al. BMC (2020) CC2

To identify and to assess factors enhancing or hindering the delivery of breast and cervical cancer screening services in Malawi with regard to accessibility, uptake, acceptability and effectiveness. Systematic review of published scientific evidence. A search of six bibliographic databases and gre... more

Download (162)

View PDF (220)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

External Link

Mycetoma: epidemiology, treatment challenges, and progress

Taha, H.; Fahal, A.; Van de Sande, W. Dovepress open access to scientific and medical research (2015) CC

Mycetoma is a specific chronic, granulomatous, inflammatory disease. It usually involves the subcutaneous tissue, most probably after traumatic inoculation of the causative organism. It has a prolonged, progressive, and indolent course, and, if untreated, it ultimately leads to destruction of the de... more

Download (764)

View PDF (1571)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (1375)

View PDF (1561)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (189)

View PDF (214)

TB Advocacy Guide - For People who use Drugs

hit.org.uk; INPUD (2019) C2

Accessed: 19.10.2019

Download (209)

View PDF (342)

Innovation in deinstitutionalization: a WHO expert survey

World Health Organization WHO (2014) C_WHO

Based on the survey, five principles for deinstitutionalization were identified: community-based services must be in place; the health workforce must be committed to change; political support at the highest and broadest levels is crucial; timing is key; and additional financial resources are needed.

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more